Larry Leon
Overview
Explore the profile of Larry Leon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin J, Zhao Y, Chen X, Donica M, Leon L, Trinquart L, et al.
Contemp Clin Trials
. 2025 Feb;
152:107860.
PMID: 40010600
Time-to-event endpoints like progression-free survival in oncology randomized trials sometimes demonstrate differential censoring patterns between study arms which can be indicative of informative censoring, depending on censoring reasons. Informative censoring...
2.
Spigel D, Chaft J, Gettinger S, Chao B, Dirix L, Schmid P, et al.
J Thorac Oncol
. 2018 May;
13(11):1733-1742.
PMID: 29775807
Introduction: The FIR phase II study (NCT01846416) evaluated the efficacy and safety of anti-programmed death-ligand 1 (PD-L1) atezolizumab in advanced NSCLC selected by tumor cell (TC) or tumor-infiltrating immune cell...
3.
Leon L, Kosty M, Jahanzeb M, Spigel D, Wozniak A, Brahmer J, et al.
Pharmacoepidemiol Drug Saf
. 2016 Jan;
25(5):569-77.
PMID: 26748833
Purpose: Bevacizumab used in combination with first-line chemotherapy confers an overall survival (OS) benefit for patients with non-squamous non-small-cell lung cancer (NSCLC). This analysis from the ARIES observational cohort study...
4.
Osarogiagbon R, Cappuzzo F, Ciuleanu T, Leon L, Klughammer B
Transl Lung Cancer Res
. 2015 Sep;
4(4):465-74.
PMID: 26380188
Background: The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined the impact of erlotinib in confirmed...
5.
Langer C, Socinski M, Patel J, Sandler A, Schiller J, Leon L, et al.
Am J Clin Oncol
. 2015 Jan;
39(5):441-7.
PMID: 25628268
Background: Patient-level data from 2 phase III studies in patients with previously untreated, advanced-stage, nonsquamous non-small cell lung cancer (NSCLC) were pooled to examine outcomes with bevacizumab and chemotherapy based...
6.
Kosty M, Wozniak A, Jahanzeb M, Leon L, Fish S, Hazard S, et al.
Target Oncol
. 2015 Jan;
10(4):509-16.
PMID: 25559289
Data from randomized, controlled trials suggest that post-induction phase (IP) treatment with bevacizumab may benefit patients with advanced non-small-cell lung cancer (NSCLC). Real-world clinical practice, however, can involve variable use...
7.
Lynch Jr T, Spigel D, Brahmer J, Fischbach N, Garst J, Jahanzeb M, et al.
J Thorac Oncol
. 2014 Aug;
9(9):1332-9.
PMID: 25122429
Introduction: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC)...
8.
Lopez-Chavez A, Young T, Fages S, Leon L, Schiller J, Dowlati A, et al.
J Thorac Oncol
. 2012 Oct;
7(11):1707-12.
PMID: 23059774
Introduction: The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin and paclitaxel (CP) in comparison with...
9.
Stepanski E, Reyes C, Walker M, Satram-Hoang S, Leon L, Wojtowicz-Praga S, et al.
Pancreas
. 2012 Jun;
42(1):32-6.
PMID: 22699203
Objectives: This retrospective study examined pancreatic cancer patients who received combination gemcitabine and erlotinib to determine if the association between rash and outcomes observed in clinical trials would be observed...
10.
Dutcher J, Leon L, Manola J, Friedland D, Roth B, Wilding G
Cancer
. 2005 Oct;
104(11):2392-9.
PMID: 16222691
Background: The current study evaluated the response rate and 6-month time to disease progression of the antiangiogenesis agent carboxyamidotriazole (CAI) in patients with metastatic renal cell carcinoma (RCC). Methods: Fifty-seven...